Literature DB >> 17196076

Degree of throat deposition can explain the variability in lung deposition of inhaled drugs.

Lars Borgström1, Bo Olsson, Lars Thorsson.   

Abstract

Inhalation is a mainstay for treatment of asthma, and lung deposition can be seen as a surrogate marker for the ensuing clinical effects. Not only absolute lung deposition, but also its variability is of interest, as it indicates the range of expected lung deposition in an individual patient when prescribing the drug and the expected day-to-day variability when using it. A literature survey found 71 studies with relevant information on lung deposition and its variability. Further characteristics of the studies, such as if the subjects were healthy or asthmatics, adults or children, and what device that was used, were noted. In all, 187 data points were included. Variability in lung deposition was depicted as a function of mean lung deposition; for the entire data set and for subsets thereof. Independent of device type or subject category high lung deposition was associated with low relative variability and vice versa. Using a published throat deposition model, the observed correlation of lung deposition variability to mean lung deposition could be explained as being determined largely by the extent of and variability in throat deposition. We hypothesize that throat deposition is the major determinant for lung deposition of an inhaled aerosol, and its absolute variability will largely be determined by the absolute variability in throat deposition. The relative variability in lung deposition will therefore tend to be high for low lung deposition and low for high lung deposition. Consequently, low relative variability in lung deposition can only be attained if high lung deposition is achieved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196076     DOI: 10.1089/jam.2006.19.473

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  37 in total

1.  Evaluation of enhanced condensational growth (ECG) for controlled respiratory drug delivery in a mouth-throat and upper tracheobronchial model.

Authors:  Michael Hindle; P Worth Longest
Journal:  Pharm Res       Date:  2010-05-08       Impact factor: 4.200

2.  Effect of intersubject variability of extrathoracic morphometry, lung airways dimensions and respiratory parameters on particle deposition.

Authors:  Majid Hussain; Winker-Heil Renate; Hofmann Werner
Journal:  J Thorac Dis       Date:  2011-09       Impact factor: 2.895

3.  Condensational growth of combination drug-excipient submicrometer particles for targeted high efficiency pulmonary delivery: comparison of CFD predictions with experimental results.

Authors:  P Worth Longest; Michael Hindle
Journal:  Pharm Res       Date:  2011-09-27       Impact factor: 4.200

4.  Characterization of Nanoaerosol Size Change During Enhanced Condensational Growth.

Authors:  P Worth Longest; James T McLeskey; Michael Hindle
Journal:  Aerosol Sci Technol       Date:  2010-06-01       Impact factor: 2.908

5.  The interaction between the oropharyngeal geometry and aerosols via pressurised metered dose inhalers.

Authors:  T Ehtezazi; I Saleem; I Shrubb; D R Allanson; I D Jenkinson; C O'Callaghan
Journal:  Pharm Res       Date:  2009-11-10       Impact factor: 4.200

6.  Product lifecycle approach to cascade impaction measurements.

Authors:  Terrence P Tougas; Dave Christopher; Jolyon Mitchell; Svetlana Lyapustina; Michiel Van Oort; Richard Bauer; Volker Glaab
Journal:  AAPS PharmSciTech       Date:  2011-02-01       Impact factor: 3.246

7.  Improving the lung delivery of nasally administered aerosols during noninvasive ventilation-an application of enhanced condensational growth (ECG).

Authors:  P Worth Longest; Geng Tian; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-03-16       Impact factor: 2.849

Review 8.  Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs.

Authors:  Worth Longest; Benjamin Spence; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-07-09       Impact factor: 2.849

Review 9.  The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Authors:  Jeffry Weers; Andy Clark
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

10.  Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery.

Authors:  Erin M Wilson; J Christopher Luft; Joseph M DeSimone
Journal:  Pharm Res       Date:  2018-08-23       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.